Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Gabriele Luppi, Jean–Marc Phelip et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 61